GlassScriptPhysician profile
Jean Woo
NPI 1033426945
$3,164.76
in general payments reported to CMS, 2019-2025
22 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $376 · 2024: $1,044 · 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,327 · Education: $80.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.49 |
| Education | $80.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $531.86 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $462.62 | 2024-2025 | Dupixent |
| Janssen Biotech, INC. | $362.68 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $277.31 | 2021-2025 | |
| Amgen INC. | $260.28 | 2021-2025 | Otezla |
| Incyte Corporation | $204.69 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $167.36 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $165.08 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $120.74 | 2021-2025 | |
| Organon LLC | $98.42 | 2025 | Vtama |
| Leo Pharma INC. | $88.02 | 2024-2025 | Adbry |
| Galderma Laboratories, L.P. | $84.28 | 2025 | Nemluvio |
| Lilly USA, LLC | $72.55 | 2024-2025 | Ebglyss, Taltz, Olumiant |
| Biofrontera INC. | $59.62 | 2021-2022 | |
| Almirall LLC | $39.79 | 2024-2025 | Klisyri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $36.72 | 2024 | Vtama |
| Botanix Sb INC | $35.23 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $27.50 | 2025 | |
| Arcutis Biotherapeutics, INC. | $23.26 | 2025 | Zoryve |
| Ucb, INC. | $19.65 | 2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.63 | 2025 | Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Woo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.